mobic and Renal-Insufficiency

Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Drug Interactions; Humans; Hypertension; Lisinopril; Male; Meloxicam; Middle Aged; Osteoarthritis, Knee; Pain Management; Renal Insufficiency; Thiazines; Thiazoles

Doxorubicin-induced renal toxicity overshadows its anticancer effectiveness. This study is aimed at assessing the possible modulator effects of meloxicam, a cyclooxigenase-2 inhibitor, on doxorubicin-induced nephrotoxicity in mice and exploring some of the modulator mechanisms. Forty male mice were divided for treatment, for 2 weeks, with saline, meloxicam (daily), doxorubicin (twice/week), or both meloxicam and doxorubicin. Doxorubicin induced a significant increase in relative kidney weight to body weight, kidney lipid perooxidation, plasma levels of interleukin-6 and tumor necrosis factor-α, kidney caspase-3 activity, and kidney prostaglandin E2 (PGE2) content. Doxorubicin disturbed kidney histology, abrogated renal function tests (serum creatinine, uric acid, and blood urea nitrogen), induced a significant decrease in antioxidant enzyme activities (superoxide dismutase, glutathione peroxidase, and catalase) and reduced glutathione (GSH) content. The administration of meloxicam with doxorubicin mitigated all doxorubicin-disturbed parameters. Meloxicam ameliorated doxorubicin-induced renal injury via inhibition of inflammatory PGE2, inflammatory cytokines, caspase-3 activity, antioxidant effect, and free radical scavenging activity.

Topics: Animals; Caspase 3; Dinoprostone; Doxorubicin; Humans; Interleukin-6; Lipid Peroxidation; Male; Meloxicam; Mice; Neoplasms; Oxidative Stress; Renal Insufficiency; Thiazines; Thiazoles; Tumor Necrosis Factor-alpha

Topics: Adverse Drug Reaction Reporting Systems; Animals; Anthelmintics; Benzimidazoles; Cat Diseases; Cats; Dogs; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Meloxicam; Off-Label Use; Population Surveillance; Renal Insufficiency; Thiazines; Thiazoles; Triclabendazole; United Kingdom; Vaccination